{"id":"W4200262376","doi":"10.1016/j.clgc.2021.12.003","title":"Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; University of Ottawa; Centre Hospitalier de l’Université de Montréal; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Foothills Medical Centre; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Renal cell carcinoma; Internal medicine; Cohort; Oncology; Kidney cancer; Adverse effect; Expanded access; Cancer; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003980277,0.0001432741,0.000333199,0.0004187011,0.0003944064,0.0009067243,0.0002706311,0.0003937037,0.00124268],"category_scores_gemma":[0.001704762,0.0001773517,0.0004955988,0.0008909443,0.0002794194,0.0005520263,0.0003314331,0.0006082953,0.00016798],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008321928,"about_ca_system_score_gemma":0.0006409055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005969379,"about_ca_topic_score_gemma":0.006207743,"domain_scores_codex":[0.9994917,0.0001128542,0.00005485826,0.0001376002,0.00008496427,0.0001180966],"domain_scores_gemma":[0.9989789,0.0001799234,0.0004916508,0.00005632426,0.00009169469,0.000201634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004895351,0.00005305752,0.9965065,0.00001580122,0.0001201411,0.0001036307,0.00004819539,0.0001050244,0.0002763571,0.00003581755,0.0002024658,0.002043441],"study_design_scores_gemma":[0.00002930397,0.0003346299,0.997153,0.00001109433,0.0001038057,0.000603672,0.0003307523,0.0006594381,0.0001212906,0.00005128314,0.0005912464,0.00001046381],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987069,0.0004651026,0.00003374345,0.00009322732,0.000006831342,0.000004240766,0.0003372137,0.000002501554,0.0003502721],"genre_scores_gemma":[0.9993932,0.0001434868,0.00002376122,0.00005571719,0.00001328014,0.000003839005,0.0003000663,0.000001645622,0.00006509702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005969379,"threshold_uncertainty_score":0.01186925,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07943066627634919,"score_gpt":0.3662064179276324,"score_spread":0.2867757516512832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}